In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Mechanical dispersion by speckle tracking imaging in Brugada syndrome patients

Session Clinical impact of strain imaging

Speaker Esther Scheirlynck

Congress : ESC Congress 2018

  • Topic : imaging
  • Sub-topic : Tissue Doppler, Speckle Tracking and Strain Imaging
  • Session type : Abstract Session
  • FP Number : 5021

Authors : E Scheirlynck (Brussels,BE), S Van Malderen (Sint-Niklaas,BE), A Motoc (Brussels,BE), J Sieira (Brussels,BE), C De Asmundis (Brussels,BE), GB Chierchia (Brussels,BE), P Brugada (Brussels,BE), S Droogmans (Brussels,BE), B Cosyns (Brussels,BE)

15 views

Authors:
E. Scheirlynck1 , S. Van Malderen2 , A. Motoc1 , J. Sieira1 , C. De Asmundis1 , G.B. Chierchia1 , P. Brugada1 , S. Droogmans1 , B. Cosyns1 , 1University Hospital (UZ) Brussels, Centrum voor Hart- en Vaatziekten - Brussels - Belgium , 2AZ Nikolaas, Cardiology Department - Sint-Niklaas - Belgium ,

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 1043-1044

Background: Brugada syndrome (BrS) is associated with an increased risk for severe ventricular arrhythmias and sudden cardiac death. Although labeled as a disease occurring in structurally normal hearts, functional alterations in some patients, mostly affecting the right ventricle (RV) and less often the left ventricle (LV), have been identified using new imaging techniques. Mechanical dispersion (MD) by speckle tracking imaging has been previously used to predict arrhythmic events in various cardiomyopathies.

Purpose: To evaluate if LV and RV global longitudinal strain (GLS) and MD by speckle tracking analysis differ between BrS patients and healthy matched controls.

Methods: We included 148 patients with BrS and 67 healthy controls. Patients with coronary heart disease were excluded. For each patient, speckle tracking analysis was performed in 16 LV and 6 RV segments. The time to peak myocardial strain in each segment was measured as the time from onset of the QRS complex on the ECG to maximum myocardial shortening. GLS was defined as the mean of the peak strain in the 16 LV segments and the 3 RV free wall segments. MD was defined as the standard deviation of the time to peak in respectively the 16 LV segments, the 6 RV segments and the 3 RV free wall segments.

Results: LV, RV and RV free wall MD were significantly higher in patients with BrS than in healthy controls [38 (±11) vs. 33 (±8) ms, P<0.001; 29 (±17) vs. 24 (±14) ms, P<0.05; 20 (±17) vs. 15 (±11) ms, P=0.004]. LV and RV GLS did not differ significantly between BrS patients and healthy controls [-18.7 (±2.3) vs. -19.0 (±1.9) %, P=0.39 and -25.9 (±5.2) vs. -25.8 (±3.5) %, P=0.90].

Conclusion: BrS patients had a higher MD than healthy controls, both in the LV and RV. Both LV and RV GLS were not significantly altered in BrS compared to healthy controls. Therefore, MD by speckle tracking might be a potential marker for the risk stratification of arrhythmic events in BrS.

Demographics and Speckle tracking data
All (215)BrS (148)Controls (67)p-value
Age (y)45±1445±1445±130.724
Female n (%)108 (50)73 (49)35 (51)0.884
GLS LV (%)-18.8±2.2-18.7±2.3-19.0±1.90.392
MD LV (ms)36±1138±1133±8<0.001
GLS RV (%)-25.8±4.7-25.9±5.2-25.8±3.50.896
MD RV (ms)27±1629±1724±140.046
MD RV free wall (ms)19±1620±1715±110.004
BrS = Brugada syndrome, GLS = global longitudinal strain, LV = left ventricle, MD = mechanical dispersion, RV = right ventricle.
LV mechanical dispersion

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are